# US 2024/0393353 A1 · Biomarker for cancer diagnosis and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0393353 A1
- Document ID: US20240393353A1
- Status: Published application
- Kind: A1
- Application number: 18/698,991
- Filed: 2022-08-11
- Published: 2024-11-28
- Earliest claimed: 2021-10-06
- Assignees: Innobation Bio Co., Ltd.
- Applicants: Innobation Bio Co., Ltd.
- Inventors: Seung Koo KIM; Ki Tae KIM
- Web page: https://patentgrep.com/patent/US20240393353A1

## CPC

- G01N 33/5752: of the lungs
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 30/88: Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N 33/57515: of the breast
- G01N 33/57525: of the liver or pancreas
- G01N 33/5753: of the stomach or small intestine
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 30/72: Mass spectrometers {(mass spectrometers per se H01J49/00)}
- G01N 30/86: Signal analysis
- G01N 2030/027: {Liquid chromatography}
- G01N 2030/8813: {biological materials}
- G01N 2030/884: {organic compounds}
- G01N 2333/4716: Complement proteins, e.g. anaphylatoxin, C3a, C5a
- G01N 2333/4728: alpha-Glycoproteins
- G01N 2405/04: Phospholipids, i.e. phosphoglycerides
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to biomarkers for cancer diagnosis and uses thereof, and more particularly to a composition for diagnosing or predicting cancer prognosis, comprising an agent for measuring levels of at least one biomarker selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG) and Osteopontin in blood, and a method of using the biomarker to provide information about the diagnosis or prognosis of cancer. In the present invention, it was confirmed that the level of complement component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), histidine-rich glycoprotein (HRG), and/or osteopontin (OPN) in blood of lung and/or hepatic cancer patients has been found to have different patterns than that of normal individuals, and the combination of these markers has been shown to improve the diagnosis of various cancers, including lung or hepatic cancer. Accordingly, the biomarkers of the present invention can be useful in cancer diagnosis and prognosis.

## Claims

### Claim 1

A biomarker composition for diagnosing cancer, wherein the composition comprises at least one biomarker selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG), and Osteopontin (OPN), and wherein the biomarker is derived from blood.

### Claim 2 (depends on 1)

The biomarker composition for diagnosing cancer of claim 1, wherein blood is whole blood, plasma, or serum.

### Claim 3 (depends on 1)

The biomarker composition for diagnosing cancer of claim 1, wherein the cancer is lung cancer, pancreatic cancer, biliary tract cancer, colorectal cancer, breast cancer, gastric cancer, brain tumor, kidney cancer, hepatic cancer, or cervical cancer.

### Claim 4 (depends on 1)

The biomarker composition for diagnosing cancer of claim 1, wherein the lysophosphatidylcholine (LPC) is lysophosphatidylcholine 16:0 (LPC16) or lysophosphatidylcholine 18:0 (LPC18).

### Claim 5 (depends on 1)

The biomarker composition for diagnosing cancer of claim 1,
where the concentration of C7 biomarker in blood is higher than that of a normal control;
where the concentration of OPN biomarker in blood is higher than that of a normal control;
where the concentration of DC biomarker in blood is lower than that of a normal control;
where the concentration of LPC biomarker in blood is lower than that of a normal control; or
where the concentration of Histidine-Rich Glycoprotein (HRG) biomarker in blood is lower than that of a normal control group,
it is diagnosed or determined to have cancer.

### Claim 6 (depends on 5)

The biomarker composition for diagnosing cancer of claim 5,
where the cut-off value of C7 biomarker is 230 to 240 μg/ml, and the concentration of C7 in blood is above or equal to the cut-off value;
where the cutoff value for DC biomarker is 14 to 17 ng/mL, and the concentration of DC in blood is below or equal to the cutoff value;
where the cutoff value for HRG biomarker is 90 to 95 μg/ml, and a concentration of HRG in blood below or equal to the cutoff value; or
where the cutoff value for LPC biomarker is 40 to 45 μg/ml, and a concentration of LPC in blood below the cut-off value,
it is diagnosed or determined to have lung cancer.

### Claim 7 (depends on 5)

The biomarker composition for diagnosing cancer of claim 5,
where the cut-off value of C7 biomarker is 245 to 270 μg/ml, and the concentration of C7 biomarker in blood is above or equal to the cut-off value;
where the cutoff value for DC biomarker is 12 to 15 ng/ml, and the concentration of DC biomarker in blood is below or equal to the cutoff value;
where the cutoff value for HRG biomarker is 85 to 90 μg/ml, and the concentration of HRG biomarker in blood is below or equal to the cutoff value;
where the cutoff value for OPN biomarker is 80 to 90 ng/mL, and the concentration of OPN biomarker in blood above or equal to the cutoff value, or
where the cut-off value of LPC biomarker is 44 to 50 μg/ml, and the concentration of LPC biomarker in blood below the cut-off value,
it is diagnosed or determined to have hepatic cancer.

### Claim 8 (depends on 1)

The biomarker composition for diagnosing cancer of claim 1,
(1) where the biomarkers are C7 and DC, the cancer is diagnosed by the ratio of C7 concentration:DC concentration (C7/DC);
(2) where the biomarkers are C7 and LPC, the cancer is diagnosed by the ratio of C7 concentration:LPC concentration (C7/LPC);
(3) where the biomarkers are C7 and HRG, the cancer is diagnosed by the ratio of C7 concentration:HRG concentration (C7/HRG);
(4) where the biomarkers are C7, DC, and LPC, the cancer is diagnosed by the ratio of C7 concentration:(sum of DC concentration and LPC concentration) (C7/(DC+LPC));
(5) where the biomarkers are C7, DC, and HRG, the cancer is diagnosed by the ratio of C7 concentration:(sum of DC concentration and HRG concentration) (C7/(DC+HRG));
(6) where the biomarkers are C7, DC, HRG, and LPC, the cancer is diagnosed by the ratio of C7 concentration:(sum of DC concentration, HRG concentration and LPC concentration) (C7/(DC+HRG+LPC));
(7) where the biomarkers are C7, HRG, and LPC, the cancer is diagnosed by the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) (C7/(HRG+LPC));
(8) where the biomarkers are OPN and DC, the cancer is diagnosed by the ratio of OPN concentration:DC concentration (OPN/DC);
(9) where the biomarkers are OPN and LPC, the cancer is diagnosed by the ratio of OPN concentration:LPC concentration (OPN/LPC);
(10) where the biomarkers are OPN and HRG, the cancer is diagnosed by the ratio of OPN concentration:HRG concentration (OPN/HRG);
(11) where the biomarkers are OPN, DC, and LPC, the cancer is diagnosed by the ratio of OPN concentration:(sum of DC concentration and LPC concentration) (OPN/(DC+LPC)); or
(12) where the biomarkers are OPN, DC, and HRG, the cancer is diagnosed by the ratio of OPN concentration:(sum of DC concentration and HRG concentration) (OPN/(DC+HRG)).

### Claim 9 (depends on 8)

The biomarker composition for diagnosing cancer of claim 8,
(1) where the cut-off value for the ratio of C7 concentration:DC concentration (C7/DC) is 10 to 12 and the ratio of C7 concentration:DC concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(2) where the cut-off value for the ratio of C7 concentration:LPC concentration (C7/LPC) is 3.5 to 5 and the ratio of C7 concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(3) where the cut-off value for the ratio of C7 concentration:HRG concentration (C7/HRG) is 2 to 2.5 and the ratio of C7 concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(4) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and LPC concentration) (C7/(DC+LPC)) is 2.5˜3.0 and the ratio of C7 concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer;
(5) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and HRG concentration) (C7/(DC+HRG)) is 1.5 to 2.0 and the ratio of C7 concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer;
(6) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration, HRG concentration and LPC concentration) (C7/(DC+HRG+LPC)) is 1 to 1.5 and the ratio of C7 concentration:(sum of DC concentration, HRG concentration and LPC concentration) in blood, plasma or serum is above or equal to the cut-off value, the cancer is lung cancer;
(7) where the cut-off value for the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) (C7/(HRG+LPC)) is 1.2˜2 and the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer;
(8) where the cut-off value for the ratio of OPN concentration:DC concentration (OPN/DC) is 3 to 5 and the ratio of OPN concentration:DC concentration in blood is above or equal to the cutoff value, the cancer is lung cancer;
(9) where the cut-off value for the ratio of OPN concentration:LPC concentration (OPN/LPC) is 1.5 to 2.0 and the ratio of OPN concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(10) where the cut-off value for the ratio of OPN concentration:HRG concentration (OPN/HRG) is 0.8 to 1.2 and the ratio of OPN concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(11) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and LPC concentration) (OPN/(DC+LPC)) is 0.9 to 1.5 and the ratio of OPN concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer; or
(12) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and HRG concentration) (OPN/(DC+HRG)) is 0.5 to 1.2 and the ratio of OPN concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer.

### Claim 10 (depends on 8)

The biomarker composition for diagnosing cancer of claim 8,
(1) where the cut-off value for the ratio of C7 concentration:DC concentration (C7/DC) is 8 to 12 and the ratio of C7 concentration:DC concentration ratio in blood is above or equal to the cutoff value, the cancer is hepatic cancer;
(2) where the cut-off value for the ratio of C7 concentration:LPC concentration ratio (C7/LPC) is 3.5 to 5 and the ratio of C7 concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(3) where the cut-off value for the ratio of C7 concentration:HRG concentration (C7/HRG) is 2 to 2.5 and the ratio of C7 concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(4) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and LPC concentration) (C7/(DC+LPC)) is 2 to 4 and the ratio of C7 concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(5) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and HRG concentration) (C7/(DC+HRG)) is 1.5˜2 and the ratio of C7 concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(6) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration, HRG concentration, and LPC concentration) (C7/(DC+HRG+LPC)) is 1.2 to 2 and the ratio of C7 concentration:(sum of DC concentration, HRG concentration, and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(7) where the cut-off value for the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) (C7/(HRG+LPC)) is 1 to 3 and the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(8) where the cut-off value for the ratio of OPN concentration:DC concentration (OPN/DC) is 3 to 5 and the ratio of OPN concentration:DC concentration in blood is above or equal to the cutoff value, the cancer is hepatic cancer;
(9) where the cut-off value for the ratio of OPN concentration:LPC concentration (OPN/LPC) is 1.5 to 2.5 and the ratio of OPN concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(10) where the cut-off value for the ratio of OPN to HRG (OPN/HRG) is 3 to 5 and the ratio of OPN concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(11) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and LPC concentration) (OPN/(DC+LPC)) is 0.8˜2 and the ratio of OPN concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer; or
(12) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and HRG concentration) (OPN/(DC+HRG)) is 0.5 to 1.2 and the ratio of OPN concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer.

### Claim 11 (depends on 1)

A composition for diagnosing cancer, comprising an agent for measuring levels in blood of the biomarker composition for diagnosing cancer of claim 1.

### Claim 12 (depends on 1)

A kit for diagnosing cancer, comprising an agent for measuring levels in blood of the biomarker composition for diagnosing cancer of claim 1.

### Claim 13

A method of providing information for diagnosing cancer, comprising
(a) measuring levels of one or more biomarkers selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG), and Osteopontin (OPN) in the patient's blood; and
(b) comparing levels of the biomarker to those from a normal control sample.

### Claim 14 (depends on 13)

The method of providing information for diagnosing cancer of claim 13, wherein blood in step (a) is whole blood, plasma, or serum.

### Claim 15 (depends on 13)

The method of providing information for diagnosing cancer of claim 13, wherein the cancer is lung cancer, pancreatic cancer, biliary tract cancer, colorectal cancer, breast cancer, gastric cancer, brain tumor, kidney cancer, hepatic cancer, or cervical cancer.

### Claim 16 (depends on 13)

The method of providing information for diagnosing cancer of claim 13, wherein the lysophosphatidylcholine (LPC) of step (a) above is lysophosphatidylcholine 16:0 (LPC16) or lysophosphatidylcholine 18:0 (LPC18).

### Claim 17 (depends on 13)

The method of providing information for diagnosing cancer of claim 13, characterized in that it further comprises the step of providing information that cancer is present,
where the concentration of C7 biomarker in blood is higher than that of a normal control;
where the concentration of OPN biomarker in blood is higher than that of a normal control;
where the concentration of DC biomarker in blood is lower than that of a normal control;
where the concentration of LPC biomarker in blood is lower than that of a normal control; or
where the concentration of Histidine-Rich Glycoprotein (HRG) biomarker in blood is lower than that of a normal control group.

### Claim 18 (depends on 17)

The method of providing information for diagnosing cancer of claim 17, characterized in that providing information that lung cancer is present,
where the cut-off value of C7 biomarker is 230 to 240 μg/ml, and the concentration of C7 in blood is above or equal to the cut-off value;
where the cutoff value for DC biomarker is 14 to 17 ng/mL, and the concentration of DC in blood is below or equal to the cutoff value;
where the cutoff value for HRG biomarker is 90 to 95 μg/ml, and a concentration of HRG in blood below or equal to the cutoff value; or
where the cutoff value for LPC biomarker is 40 to 45 μg/ml, and a concentration of LPC in blood below the cut-off value.

### Claim 19 (depends on 17)

The method of providing information for diagnosing cancer of claim 17, characterized in that providing information that hepatic cancer is present,
where the cut-off value of C7 biomarker is 245 to 270 μg/ml, and the concentration of C7 biomarker in blood is above or equal to the cut-off value;
where the cutoff value for DC biomarker is 12 to 15 ng/ml, and the concentration of DC biomarker in blood is below or equal to the cutoff value;
where the cutoff value for HRG biomarker is 85 to 90 μg/ml, and the concentration of HRG biomarker in blood is below or equal to the cutoff value;
where the cutoff value for OPN biomarker is 80 to 90 ng/mL, and the concentration of OPN biomarker in blood above or equal to the cutoff value, or
where the cut-off value of LPC biomarker is 44 to 50 μg/ml, and the concentration of LPC biomarker in blood below the cut-off value.

### Claim 20 (depends on 13)

The method of providing information for diagnosing cancer of claim 13,
(1) where the biomarkers are C7 and DC, the information for diagnosing cancer is measured or provided by the ratio of C7 concentration:DC concentration (C7/DC);
(2) where the biomarkers are C7 and LPC, the information for diagnosing cancer is measured or provided by the ratio of C7 concentration:LPC concentration (C7/LPC);
(3) where the biomarkers are C7 and HRG, the information for diagnosing cancer is measured or provided by the ratio of C7 concentration:HRG concentration (C7/HRG);
(4) where the biomarkers are C7, DC, and LPC, the information for diagnosing cancer is measured or provided by the ratio of C7 concentration:(sum of DC concentration and LPC concentration) (C7/(DC+LPC));
(5) where the biomarkers are C7, DC, and HRG, the information for diagnosing cancer is measured or provided by the ratio of C7 concentration:(sum of DC concentration and HRG concentration) (C7/(DC+HRG));
(6) where the biomarkers are C7, DC, HRG, and LPC, the information for diagnosing cancer is measured or provided by the ratio of C7 concentration:(sum of DC concentration, HRG concentration and LPC concentration) (C7/(DC+HRG+LPC));
(7) where the biomarkers are C7, HRG, and LPC, the information for diagnosing cancer is measured or provided by the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) (C7/(HRG+LPC));
(8) where the biomarkers are OPN and DC, the information for diagnosing cancer is measured or provided by the ratio of OPN concentration:DC concentration (OPN/DC);
(9) where the biomarkers are OPN and LPC, the information for diagnosing cancer is measured or provided by the ratio of OPN concentration:LPC concentration (OPN/LPC);
(10) where the biomarkers are OPN and HRG, the information for diagnosing cancer is measured or provided by the ratio of OPN concentration:HRG concentration (OPN/HRG);
(11) where the biomarkers are OPN, DC, and LPC, the information for diagnosing cancer is measured or provided by the ratio of OPN concentration:(sum of DC concentration and LPC concentration) (OPN/(DC+LPC)); or
(12) where the biomarkers are OPN, DC, and HRG, the information for diagnosing cancer is measured or provided by the ratio of OPN concentration:(sum of DC concentration and HRG concentration) (OPN/(DC+HRG)).

### Claim 21 (depends on 20)

The method of providing information for diagnosing cancer of claim 20,
(1) where the cut-off value for the ratio of C7 concentration:DC concentration (C7/DC) is 10 to 12 and the ratio of C7 concentration:DC concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(2) where the cut-off value for the ratio of C7 concentration:LPC concentration (C7/LPC) is 3.5 to 5 and the ratio of C7 concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(3) where the cut-off value for the ratio of C7 concentration:HRG concentration (C7/HRG) is 2 to 2.5 and the ratio of C7 concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(4) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and LPC concentration) (C7/(DC+LPC)) is 2.5˜3.0 and the ratio of C7 concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer;
(5) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and HRG concentration) (C7/(DC+HRG)) is 1.5 to 2.0 and the ratio of C7 concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer;
(6) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration, HRG concentration and LPC concentration) (C7/(DC+HRG+LPC)) is 1 to 1.5 and the ratio of C7 concentration:(sum of DC concentration, HRG concentration and LPC concentration) in blood, plasma or serum is above or equal to the cut-off value, the cancer is lung cancer;
(7) where the cut-off value for the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) (C7/(HRG+LPC)) is 1.2˜2 and the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer;
(8) where the cut-off value for the ratio of OPN concentration:DC concentration (OPN/DC) is 3 to 5 and the ratio of OPN concentration:DC concentration in blood is above or equal to the cutoff value, the cancer is lung cancer;
(9) where the cut-off value for the ratio of OPN concentration:LPC concentration (OPN/LPC) is 1.5 to 2.0 and the ratio of OPN concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(10) where the cut-off value for the ratio of OPN concentration:HRG concentration (OPN/HRG) is 0.8 to 1.2 and the ratio of OPN concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is lung cancer;
(11) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and LPC concentration) (OPN/(DC+LPC)) is 0.9 to 1.5 and the ratio of OPN concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer; or
(12) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and HRG concentration) (OPN/(DC+HRG)) is 0.5 to 1.2 and the ratio of OPN concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is lung cancer.

### Claim 22 (depends on 20)

The method of providing information for diagnosing cancer of claim 20,
(1) where the cut-off value for the ratio of C7 concentration:DC concentration (C7/DC) is 8 to 12 and the ratio of C7 concentration:DC concentration ratio in blood is above or equal to the cutoff value, the cancer is hepatic cancer;
(2) where the cut-off value for the ratio of C7 concentration:LPC concentration ratio (C7/LPC) is 3.5 to 5 and the ratio of C7 concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(3) where the cut-off value for the ratio of C7 concentration:HRG concentration (C7/HRG) is 2 to 2.5 and the ratio of C7 concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(4) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and LPC concentration) (C7/(DC+LPC)) is 2 to 4 and the ratio of C7 concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(5) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration and HRG concentration) (C7/(DC+HRG)) is 1.5˜2 and the ratio of C7 concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(6) where the cut-off value for the ratio of C7 concentration:(sum of DC concentration, HRG concentration, and LPC concentration) (C7/(DC+HRG+LPC)) is 1.2 to 2 and the ratio of C7 concentration:(sum of DC concentration, HRG concentration, and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(7) where the cut-off value for the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) (C7/(HRG+LPC)) is 1 to 3 and the ratio of C7 concentration:(sum of HRG concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(8) where the cut-off value for the ratio of OPN concentration:DC concentration (OPN/DC) is 3 to 5 and the ratio of OPN concentration:DC concentration in blood is above or equal to the cutoff value, the cancer is hepatic cancer;
(9) where the cut-off value for the ratio of OPN concentration:LPC concentration (OPN/LPC) is 1.5 to 2.5 and the ratio of OPN concentration:LPC concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(10) where the cut-off value for the ratio of OPN to HRG (OPN/HRG) is 3 to 5 and the ratio of OPN concentration:HRG concentration in blood is above or equal to the cut-off value, the cancer is hepatic cancer;
(11) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and LPC concentration) (OPN/(DC+LPC)) is 0.8˜2 and the ratio of OPN concentration:(sum of DC concentration and LPC concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer; or
(12) where the cut-off value for the ratio of OPN concentration:(sum of DC concentration and HRG concentration) (OPN/(DC+HRG)) is 0.5 to 1.2 and the ratio of OPN concentration:(sum of DC concentration and HRG concentration) in blood is above or equal to the cut-off value, the cancer is hepatic cancer.

### Claim 23 (depends on 13)

The method of providing information for diagnosing cancer of claim 13, wherein the measuring levels of one or more biomarkers selected from the group consisting of C7, HRG and OPN in step (a) above is performed using protein chip analysis, immunometry, ligand binding assay, matrix desorption/ionization time of flight mass spectrometry (MALDI-TOF) analysis, surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF) analysis, radioimmunoassay, radioimmunodiffusion, or ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis, liquid chromatography-mass spectrometry (LC-MS), liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS), western blot, and/or enzyme linked immunosorbent assay (ELISA).

### Claim 24 (depends on 13)

The method of providing information for diagnosing cancer of claim 13, wherein the measuring levels of one or more biomarkers selected from the group consisting of DC and LPC in step (a) above is performed using liquid chromatography-mass spectrometry (LC-MS).
